阿托伐他汀联合尤瑞克林对急性脑梗死患者临床疗效及内皮素水平的影响
发布时间：2018-12-10 08:34
【摘要】：目的观察阿托伐他汀联合尤瑞克林治疗急性脑梗死患者的临床疗效及对内皮素(ET)的影响,分析其疗效影响因素。方法 180例急性脑梗死患者按随机数字表分为观察组90例和对照组90例,两组给予常规治疗,包括抗血小板、他汀类药物、神经保护剂、改善血液循环药物,对照组他汀类药物选择阿托伐他汀,20 mg/次,qd,观察组在对照组的基础上再给予尤瑞克林治疗,0.15 PNAU/次,qd,连续治疗2 w,治疗前后进行脑卒中量表(NIHSS)评分及日常生活能力(ADL)评分,评价临床疗效,采用放射免疫分析法测定血浆ET含量,分析临床疗效的影响因素〔年龄、性别、吸烟、饮酒、高血压、糖尿病、心脏病、高脂血症、低分子肝素试验(TOAST)分型、牛津郡社区脑卒中项目(OCSP)分型〕。结果观察组临床总有效率明显高于对照组(P0.05),观察组和对照组治疗后NIHSS评分、ET水平较治疗前明显降低(P均0.05),ADL评分较治疗前明显升高(P均0.05),观察组治疗后NIHSS评分、ET水平明显低于对照组(P0.05),ADL评分明显高于对照组(P0.05)。糖尿病及TOAST分型是影响阿托伐他汀联合尤瑞克林疗法的影响因素,糖尿病患者临床疗效降低,小动脉闭塞型(SAO)患者效果更佳,年龄、性别、吸烟、饮酒、高血压、心脏病、高脂血症、OCSP分型对阿托伐他汀联合尤瑞克林疗法的疗效无影响。结论阿托伐他汀联合尤瑞克林治疗急性脑梗死患者可有效改善神经功能缺损,恢复ADL,效果明显优于常规疗法,与其对抗血管收缩有关,其效果受糖尿病及TOAST分型影响,临床医师应考虑血糖控制及临床分型,规范临床治疗。
[Abstract]:Objective to observe the clinical effect of Atto vastatin combined with eucrine in the treatment of acute cerebral infarction and its effect on endothelin (ET), and to analyze the influencing factors. Methods 180 patients with acute cerebral infarction were randomly divided into the observation group (n = 90) and the control group (n = 90). The two groups were given routine treatment, including antiplatelet, statins, neuroprotective agents, and improving blood circulation. In the control group, the statins were selected as Atto vastatin for 20 mg/, and the qd, observation group was treated with eucrine on the basis of the control group for 0. 15 PNAU/ and qd, for 2 weeks. Before and after treatment, stroke scale (NIHSS) score and ADL (ADL) score were used to evaluate clinical efficacy, plasma ET content was measured by radioimmunoassay, and the influencing factors (age, sex, smoking, alcohol consumption) were analyzed. Hypertension, diabetes, heart disease, hyperlipidemia, low molecular weight heparin test (TOAST) typing, Oxfordshire Community Stroke Project (OCSP) typing. Results the total clinical effective rate in the observation group was significantly higher than that in the control group (P0.05). The NIHSS score and ET level in the observation group and the control group were significantly lower than those before treatment (P 0.05). The NIHSS score and ET level in the observation group were significantly lower than those in the control group (P0.05), ADL score was significantly higher than that in the control group (P0.05). Diabetes mellitus and TOAST classification were the influencing factors of Atto vastatin combined with eucrine therapy. The clinical efficacy of patients with diabetes was lower than that of patients with arterio-occlusive (SAO). Age, sex, smoking, drinking, high blood pressure, heart disease, age, sex, smoking, drinking, hypertension, heart disease, Hyperlipidemia, OCSP typing had no effect on the efficacy of Atto vastatin combined with eurekline. Conclusion Atto vastatin combined with eurexacin can effectively improve the neurological function of patients with acute cerebral infarction, and the effect of ADL, recovery is better than that of routine therapy, which is related to the antivasoconstriction effect, and its effect is affected by diabetes mellitus and TOAST classification. The clinician should consider the blood sugar control and clinical classification, standardize the clinical treatment.
【作者单位】： 莱芜市人民医院保健二科;
【分类号】：R743.33
[Abstract]:Objective to observe the clinical effect of Atto vastatin combined with eucrine in the treatment of acute cerebral infarction and its effect on endothelin (ET), and to analyze the influencing factors. Methods 180 patients with acute cerebral infarction were randomly divided into the observation group (n = 90) and the control group (n = 90). The two groups were given routine treatment, including antiplatelet, statins, neuroprotective agents, and improving blood circulation. In the control group, the statins were selected as Atto vastatin for 20 mg/, and the qd, observation group was treated with eucrine on the basis of the control group for 0. 15 PNAU/ and qd, for 2 weeks. Before and after treatment, stroke scale (NIHSS) score and ADL (ADL) score were used to evaluate clinical efficacy, plasma ET content was measured by radioimmunoassay, and the influencing factors (age, sex, smoking, alcohol consumption) were analyzed. Hypertension, diabetes, heart disease, hyperlipidemia, low molecular weight heparin test (TOAST) typing, Oxfordshire Community Stroke Project (OCSP) typing. Results the total clinical effective rate in the observation group was significantly higher than that in the control group (P0.05). The NIHSS score and ET level in the observation group and the control group were significantly lower than those before treatment (P 0.05). The NIHSS score and ET level in the observation group were significantly lower than those in the control group (P0.05), ADL score was significantly higher than that in the control group (P0.05). Diabetes mellitus and TOAST classification were the influencing factors of Atto vastatin combined with eucrine therapy. The clinical efficacy of patients with diabetes was lower than that of patients with arterio-occlusive (SAO). Age, sex, smoking, drinking, high blood pressure, heart disease, age, sex, smoking, drinking, hypertension, heart disease, Hyperlipidemia, OCSP typing had no effect on the efficacy of Atto vastatin combined with eurekline. Conclusion Atto vastatin combined with eurexacin can effectively improve the neurological function of patients with acute cerebral infarction, and the effect of ADL, recovery is better than that of routine therapy, which is related to the antivasoconstriction effect, and its effect is affected by diabetes mellitus and TOAST classification. The clinician should consider the blood sugar control and clinical classification, standardize the clinical treatment.
【作者单位】： 莱芜市人民医院保健二科;
【分类号】：R743.33
【相似文献】
相关期刊论文 前10条
1 姚建华;宋春伶;杨鑫;;尤瑞克林治疗基底动脉尖综合征30例临床观察[J];中国老年学杂志;2008年18期
2 林兴建;过燕萍;徐俊;孙丰;陈俊;张颖冬;;尤瑞克林治疗短暂性脑缺血发作的疗效观察[J];山东医药;2009年01期
3 方伯言;贾玉洁;杨波;杨锐;贾宁;闵连秋;;尤瑞克林治疗短暂性脑缺血发作26例疗效观察[J];山东医药;2009年37期
4 陈玉s，
本文编号：2370290
本文链接：https://www.wllwen.com/yixuelunwen/jjyx/2370290.html
最近更新
教材专著
